ERBB2 and medulloblastoma: In most benign meningiomas, however, ErbB4 is underexpressed and co-expression of ErbB4 with ErbB2 has been associated with poor prognosis in medulloblastoma and with increased proliferation index in ependymomas (86–88, 90).